Viatris Beheer

Beheer criteriumcontroles 2/4

De CEO Viatris is Scott Smith, benoemd in Apr2023, heeft een ambtstermijn van 1.58 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 16.27M, bestaande uit 6.3% salaris en 93.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.007% van de aandelen van het bedrijf, ter waarde $ 990.82K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.3 jaar en 4.4 jaar.

Belangrijke informatie

Scott Smith

Algemeen directeur

US$16.3m

Totale compensatie

Percentage CEO-salaris	6.3%
Dienstverband CEO	1.6yrs
Eigendom CEO	0.007%
Management gemiddelde ambtstermijn	1.3yrs
Gemiddelde ambtstermijn bestuur	4.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Scott Smith's beloning veranderd ten opzichte van Viatris's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$646m
Mar 31 2024	n/a	n/a	-US$56m
Dec 31 2023	US$16m	US$1m	US$55m

Compensatie versus markt: De totale vergoeding ($USD 16.27M ) Scott } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.86M ).

Compensatie versus inkomsten: Er zijn onvoldoende gegevens om de beloning van Scott te vergelijken met de prestaties van het bedrijf.

CEO

Scott Smith (62 yo)

1.6yrs

Tenure

US$16,271,094

Compensatie

Mr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Cel...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Smith	CEO & Director	1.6yrs	US$16.27m	0.0072% $ 990.8k
Brian Roman	Chief Legal Officer	4yrs	US$4.11m	0.0057% $ 785.7k
Theodora Mistras	Chief Financial Officer	less than a year	geen gegevens	geen gegevens
Paul Campbell	Chief Accounting Officer	9.5yrs	geen gegevens	0.013% $ 1.8m
Ramkumar Rayapureddy	Chief Information Officer	less than a year	geen gegevens	geen gegevens
Andrew Enrietti	Chief People Officer	3.8yrs	geen gegevens	geen gegevens
Menassie Taddese	President of Emerging Markets	no data	geen gegevens	geen gegevens
Derek Glover	Chief Quality Officer	no data	geen gegevens	geen gegevens
Lara Ramsburg	Chief Corporate Affairs Officer	no data	geen gegevens	geen gegevens
Jeffrey Nau	President of Viatris Eye Care Division	no data	geen gegevens	geen gegevens
Philippe Martin	Chief R&D Officer	less than a year	geen gegevens	geen gegevens
Corinne Le Goff	Chief Commercial Officer	less than a year	geen gegevens	geen gegevens

1.3yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VTRS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.3 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Scott Smith	CEO & Director	1.9yrs	US$16.27m	0.0072% $ 990.8k
JoEllen Dillon	Independent Non-Executive Director	4.8yrs	US$400.01k	0.0049% $ 681.8k
Wyllie Cornwell	Independent Director	4yrs	US$370.01k	0.0051% $ 712.3k
Elisha Finney	Independent Director	1.9yrs	US$370.01k	0.0016% $ 219.0k
James Kilts	Independent Director	4yrs	US$370.01k	0.0098% $ 1.4m
Harry Korman	Independent Non-Executive Director	6.4yrs	US$375.01k	0.0080% $ 1.1m
Melina Higgins	Independent Non-Executive Chairman	11.8yrs	US$454.38k	0.015% $ 2.0m
Robert Coury	Chairman Emeritus & Senior Strategic Advisor	less than a year	US$41.50m	0.23% $ 31.4m
Mark Parrish	Independent Vice Chairman & Lead Independent Director	15.2yrs	US$450.01k	0.010% $ 1.4m
Rajiv Malik	Director	4.8yrs	US$12.48m	0.042% $ 5.9m
Richard Mark	Independent Non-Executive Director	4.8yrs	US$420.01k	0.0061% $ 839.8k
Leo Groothuis	Independent Director	1.5yrs	US$313.54k	0.0019% $ 257.8k

4.4yrs

Gemiddelde duur

63yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VTRS wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).

Viatris Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Viatris Inc., Annual General Meeting, Dec 06, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Director notifies of intention to sell stock

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Recent updates

Viatris Inc. Declares Quarterly Dividend, Payable on December 13, 2024

Viatris Inc., Annual General Meeting, Dec 06, 2024

Viatris Ahead Of Q3 Earnings: No Longer A 'Screaming' Bargain, But Still A Buy

Viatris Inc. Announces Positive Top-Line Results from Phase 3 Study of Effexor® in Japanese Adults with Generalized Anxiety Disorder (GAD)

Viatris Launches (Pr) Viagra ODF in Canada

Viatris Inc. to Report Q3, 2024 Results on Nov 07, 2024

Director recently sold US$2.3m worth of stock

Director recently sold US$3.5m worth of stock

Viatris Inc. Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress

Director notifies of intention to sell stock

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter dividend of US$0.12 announced

Viatris Inc. Revises Earnings Guidance for the Fiscal Year 2024

Viatris Inc. Declares Quarterly Dividend, Payable on September 13, 2024

Cooper Consumer Health SAS completed the acquisition of Substantially All of the Over-the-Counter Business of Viatris Inc. (NasdaqGS:VTRS).

Director recently sold US$3.6m worth of stock

Director notifies of intention to sell stock

Viatris: Revenues, Debt, Valuation And Strategy Under The Microscope

Viatris Inc. to Report Q2, 2024 Results on Aug 08, 2024

IQuest Enterprises Private Limited acquired API operations of Viatris in India.

Viatris: Skeptics Proven Right Once Again

Chief Legal Officer recently sold US$928k worth of stock

First quarter dividend of US$0.12 announced

Viatris Inc. Announces Quarterly Dividend, Payable on June 14, 2024

First quarter 2024 earnings: EPS misses analyst expectations

Inflation Reduction Act: A Bullish Catalyst For Viatris Inc.

Viatris Inc. to Report Q1, 2024 Results on May 09, 2024

Viatris Inc. Announces Launch of First Bioequivalent Generic Version of Copaxone 20 mg/mL Once-Daily in Canada

Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

Viatris Inc. Announces the Launch of RYZUMVI (Phentolamine Ophthalmic Solution) 0.75% in the United States

Viatris Stock Is Still Worth Buying

President of Developed Markets recently sold US$3.0m worth of stock

Insud Pharma S.L.U. acquired Women Healthcare business of Viatris Inc. (NasdaqGS:VTRS).

President & Executive Director exercised options and sold US$3.3m worth of stock

Up 25%, I Still Believe 4%-Yielding Viatris Is Up To 60% Undervalued

Fourth quarter dividend of US$0.12 announced

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on March 18, 2024

Viatris Inc. to Report Fiscal Year 2023 Results on Feb 28, 2024

From Euphoria To Reality: Viatris' Tale Of Market Whirlwind

Viatris Announces CFO Changes

Viatris Inc. Appoints Leo Groothuis to Serve on the Compliance and Risk Oversight Committee, Executive Committee and Governance and Sustainability Committee

Upcoming dividend of US$0.12 per share at 5.2% yield

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Declares Quarterly Dividend, Payable on December 15, 2023

Viatris Inc., Annual General Meeting, Dec 15, 2023

Now 21% undervalued after recent price drop

Viatris Inc. Announces That Its President, Rajiv Malik, Will Be Retiring as an Executive of the Company Effective April 1, 2024

Viatris Inc. to Report Q3, 2023 Results on Nov 07, 2023

Viatris Inc. and Ocuphire Pharma, Inc. Announce Fda Approval of Ryzumvl™? (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (E.G., Tropicamide) Agents

Viatris Reportedly in Talks to Sell European OTC Assets to CVC

Viatris Inc. Announces U.S. FDA Tentative Approval of Paediatric Formulation of Abacavir (ABC)/Dolutegravir (DTG)/Lamivudine (3TC), Once-Daily Treatment for Children Living with HIV

Upcoming dividend of US$0.12 per share at 4.3% yield

Consensus EPS estimates increase by 11%

Viatris Inc. Declares Quarterly Dividend, Payable on September 15, 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Viatris Inc. and Kindeva Drug Delivery L.P. Announces Launch of Breyna (Budesonide and Formoterol Fumarate Dihydrate) Inhalation Aerosol

Viatris Inc. to Report Q2, 2023 Results on Aug 07, 2023

Holzer & Holzer, LLC Announces A Class Action Lawsuit Has Been Filed Against Viatris Inc

Viatris Inc. Announces Board Changes

Johnson Fistel, LLP Files Class Action Lawsuit Against Viatris Inc

Upcoming dividend of US$0.12 per share at 5.1% yield

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Viatris Inc. Reaffirms Revenue Guidance for the Full-Year 2023

CEO & Executive Director exercised options and sold US$972k worth of stock

CEO & Executive Director exercised options and sold US$631k worth of stock

Full year 2022 earnings: EPS exceeds analyst expectations

Biocon Plans to Sell Stake in Biologics Arm to Pare Debt